

# **Data Sheet**

Product Name: Monastrol	
Cat. No.: CS-6183	
<b>CAS No.:</b> 329689-23-8	
Molecular Formula: C <sub>14</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub> S	
Molecular Weight: 292.35	
Target:Apoptosis; Kinesin	
Pathway: Apoptosis; Cell Cycle	/DNA Damage; Cytoskeleton
<b>Solubility:</b> DMSO : ≥ 33 mg/mL	(112.88 mM)

OH

#### **BIOLOGICAL ACTIVITY:**

Monastrol is a potent and cell-permeable inhibitor of the mitotic **kinesin Eg5** with an **IC**<sub>50</sub> value of 14  $\mu$ M. IC50 & Target: IC50: 14  $\mu$ M (Eg5)<sup>[3]</sup> *In Vitro:* Monastrol is a small, cell-permeable molecule that arrests cells in mitosis by specifically inhibiting Eg5, a member of the Kinesin-5 family. Monastrol treatment of dividing cells results in spindle collapse and cell cycle arrest with a monoastral spindle, which is similar to the phenotype observed when Eg5 is inhibited by anti-Eg5 antibodies<sup>[1]</sup>. Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cell lines. Monastrol treatment can decrease cell viability in MCF-7 tumor cells. Real-time cell growth kinetic analysis showed a decrease in the proliferation of MCF-7 cells exposed to monastrol [2].

#### PROTOCOL (Extracted from published papers and Only for reference)

**Cell Assay:** <sup>[2]</sup>The cytotoxicity assay is performed with MTT. Cells are seeded in 96-well culture plates (5000 cells/well) and incubated for 24 h for stabilization. After this period, the following treatments are administered for 24 and 48 h: vehicle control (0.5 % DMSO); 1 µM doxorubicin and monastrol at 5, 25, 50, 75, and 100 µM. After each time of treatment, the medium is withdrawn, serum-free media containing 0.5 mg/mL MTT salt is added and incubated for 4 h, and formazan crystal products are diluted<sup>[2]</sup>.

#### **References:**

[1]. Cochran JC, et al. Monastrol inhibition of the mitotic kinesin Eg5. J BiolChem. 2005 Apr 1;280(13):12658-67.

[2]. Marques LA, et al. Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells. Naunyn Schmiedebergs Arch Pharmacol. 2016 Dec;389(12):1279-1288.

[3]. Mayer TU, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999 Oct 29;286(5441):971-4.

#### CAIndexNames:

5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-4-(3-hydroxyphenyl)-6-methyl-2-thioxo-, ethyl ester

### SMILES:

O=C(C1=C(C)NC(NC1C2=CC=CC(O)=C2)=S)OCC

## Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128	Fax: 888-484-5008	E-mail: sales@ChemScene.com
Address: 1	Deer Park Dr, Suite Q, Monmouth	Junction, NJ 08852, USA